Core Viewpoint - The announcement highlights that the company has received approval from the National Medical Products Administration of China for its self-developed chemical Class 1 new drug SYH2061 injection, a double-stranded small interfering RNA (siRNA) drug, to conduct clinical trials in China [1] Group 1: Product Details - SYH2061 is designed for liver-targeted delivery of siRNA through the conjugation of N-acetylgalactosamine (GalNAc) and aims to effectively reduce levels of complement protein C5 [1] - The drug is administered subcutaneously and is the first domestically developed ultra-long-acting siRNA drug to lower C5 levels, suitable for treating IgA nephropathy and other complement-mediated diseases [1] Group 2: Clinical Development and Advantages - Preclinical studies indicate that SYH2061 demonstrates superior drug activity and sustained efficacy compared to similar siRNA products, showcasing long-lasting effects, good safety profiles, and high patient compliance [1] - The product has significant clinical development value due to its differentiated advantages in drug action and safety [1]
石药集团：SYH2061注射液(双链小干扰RNA药物)在中国获临床试验批准